The Role of Cytochrome P450 3A5 Enzyme on the Metabolism of Tacrolimus in Rats

Purpose: The present study was designed to determine the effect ratio of CYP3A5 on the metabolism of tacrolimus that is used as an immunosuppressant for tissue transplantation. Methods: To determine the role of CYP3A4 and CYP3A5 on tacrolimus metabolism, rats were divided into five groups as: group 1 (control group, tacrolimus only 1 mg/kg i.v.), group 2 (pretreated with ritonavir 5 mg/kg, i.v. 1 h before administration of tacrolimus), group 3 (pretreated with indinavir 10 mg/kg, i.v. 1 hour before administration of tacrolimus), groups 4 and 5, in addition to the protocol of groups 2 and groups 3. Dexamethasone (100 mg/kg, p.o.) was administered for 2 days before the experimental study to each group. To estimate the area under curve (AUC) of tacrolimus, the blood samples were collected after 15, 30, 60, 75, and 90 min and after 2, 3, 4, 8, and 24 h, and MEIA method was used to determine whole blood levels of tacrolimus. Results: Although the AUCs of tacrolimus in group 2 (533.5±139.85 ng.h/mL) and group 3 (3428±683 ng.h/mL) were higher than the control group (394±127 ng.h/mL), the only significant difference was found in ritonavir pretreated group (group 3). In dexamethasone pretreated groups, the AUC values were similar to control group. Conclusion: These results suggest that the role of CYP3A5 enzyme has to be taken into account for probable drug interactions and sufficient immunosuppression in patients who are treated with tacrolimus.

[1]  J. D. de Vries,et al.  Tacrolimus pharmacokinetics and pharmacogenetics: influence of adenosine triphosphate‐binding cassette B1 (ABCB1) and cytochrome (CYP) 3A polymorphisms , 2007, Fundamental & clinical pharmacology.

[2]  U. Christians,et al.  Functional interactions between P-glycoprotein and CYP3A in drug metabolism , 2005, Expert opinion on drug metabolism & toxicology.

[3]  C. Ernest,et al.  Mechanism-Based Inactivation of CYP3A by HIV Protease Inhibitors , 2005, Journal of Pharmacology and Experimental Therapeutics.

[4]  T. Habuchi,et al.  Influence of CYP3A5 and MDR1 (ABCB1) Polymorphisms on the Pharmacokinetics of Tacrolimus in Renal Transplant Recipients , 2004, Transplantation.

[5]  A. McLachlan,et al.  Changes in Tacrolimus Distribution in Blood and Plasma Protein Binding Following Liver Transplantation , 2004, Therapeutic drug monitoring.

[6]  G. Bessard,et al.  Protease inhibitors and diltiazem increase tacrolimus blood concentration in a patient with renal transplantation: a case report , 2004, European Journal of Clinical Pharmacology.

[7]  K. Inui,et al.  Effects of Intestinal and Hepatic Metabolism on the Bioavailability of Tacrolimus in Rats , 1998, Pharmaceutical Research.

[8]  K. Iwasaki,et al.  Oral Absorption of FK506 in Rats , 1993, Pharmaceutical Research.

[9]  P. Beaune,et al.  Impact of cytochrome P450 3A5 genetic polymorphism on tacrolimus doses and concentration-to-dose ratio in renal transplant recipients12 , 2003, Transplantation.

[10]  J. Fung,et al.  Effect of coadministered lopinavir and ritonavir (Kaletra) on tacrolimus blood concentration in liver transplantation patients , 2003, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[11]  E. Schuetz,et al.  Interaction of Cytochrome P450 3A Inhibitors with P-Glycoprotein , 2002, Journal of Pharmacology and Experimental Therapeutics.

[12]  J. Polli,et al.  Induction of P-glycoprotein and cytochrome P450 3A by HIV protease inhibitors. , 2001, Drug metabolism and disposition: the biological fate of chemicals.

[13]  T. Murakami,et al.  Pharmacokinetic interaction of cytochrome P450 3A-related compounds with rhodamine 123, a P-glycoprotein substrate, in rats pretreated with dexamethasone. , 2001, Drug metabolism and disposition: the biological fate of chemicals.

[14]  G. Plosker,et al.  Tacrolimus: a further update of its pharmacology and therapeutic use in the management of organ transplantation. , 2000, Drugs.

[15]  P. Vouros,et al.  Metabolism of the human immunodeficiency virus protease inhibitors indinavir and ritonavir by human intestinal microsomes and expressed cytochrome P4503A4/3A5: mechanism-based inactivation of cytochrome P4503A by ritonavir. , 1998, Drug metabolism and disposition: the biological fate of chemicals.

[16]  L. Benet,et al.  Modulation of P-glycoprotein expression by cytochrome P450 3A inducers in male and female rat livers. , 1998, Biochemical pharmacology.

[17]  J. Lin,et al.  Hepatic and intestinal metabolism of indinavir, an HIV protease inhibitor, in rat and human microsomes. Major role of CYP3A. , 1997, Biochemical pharmacology.

[18]  S K Balani,et al.  Species differences in the pharmacokinetics and metabolism of indinavir, a potent human immunodeficiency virus protease inhibitor. , 1996, Drug metabolism and disposition: the biological fate of chemicals.

[19]  A. D. Rodrigues,et al.  Cytochrome P450-mediated metabolism of the HIV-1 protease inhibitor ritonavir (ABT-538) in human liver microsomes. , 1996, The Journal of pharmacology and experimental therapeutics.

[20]  J. Idle,et al.  The role of individual human cytochromes P450 in drug metabolism and clinical response. , 1992, Trends in pharmacological sciences.